JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析

2021-06-11 Nebula MedSci原创

具有不良预后因素的亚组患者可从ixazomib-Rd治疗中获得更大的OS效益

双盲、安慰剂为对照的3期TOURMALINE-MM1研究表明伊沙佐米-来那度胺-地塞米松（ixazomib-Rd）方案相比安慰剂-Rd能显著改善复发/难治性多发性骨髓瘤患者的无进展生存期。本文报告了该研究总生存期（OS）的最终分析结果。

在该试验中，患者被随机分至ixazomib-Rd组（360人）或安慰剂-Rd组（362人），并根据既往治疗次数（1次 vs 2/3次）、蛋白酶体抑制剂（PI）暴露史（有 vs 无）和疾病分期（I-II期 vs III期）分层。总生存期（OS）是关键的次要终点。

意向治疗人群和不同亚组的总生存期

中位随访85个月后，ixazomib-Rd组和安慰剂-Rd组的中位OS分别为53.6 vs 51.6个月（风险比[HR] 0.939，p=0.495）。在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益：对任何治疗都不敏感（HR 0.794）、对最后一次治疗不敏感（0.742）、65-75岁（0.757）、III期（0.799）、既往治疗过2-3次（0.845）、高风险细胞遗传学（0.870）、高风险细胞遗传学和（或）1q21扩增（0.862）。

各种高风险细胞遗传学特征患者的总生存期

研究治疗后，ixazomib-Rd组 vs 安慰剂-Rd组分别有71.7% vs 69.9%的患者接受了其他抗癌治疗，其中分别有24.7% vs 33.9%的患者接受了达雷木单抗治疗，71.8% vs 76.9%的患者接受了PI治疗。

两组原发恶性肿瘤的新发率相近：ixazomib-Rd组（10.3%）、安慰剂-Rd组（11.9%）。无新发安全性问题。

综上，在本次分析中，ixazomib-Rd与安慰剂-Rd的无进展生存获益并未转化为具有统计学意义的OS获益。具有不良预后因素的亚组患者可从ixazomib-Rd治疗中获得更大的OS效益。

原始出处：

Paul G. Richardson, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology. June 10, 2021

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1007070, encodeId=dae2100e07011, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 11 21:21:03 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Nov 04 16:01:33 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25666, encryptionId=3ec02566625, topicName=伊沙佐米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b311689214, createdName=vividelife, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528760, encodeId=69e21528e6077, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973170, encodeId=d94b9e3170df, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sat Jun 12 22:41:00 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972931, encodeId=63139e2931d4, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Fri Jun 11 19:53:53 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
2021-08-11 涂涂0518

学习中

83 0
[GetPortalCommentsPageByObjectIdResponse(id=1007070, encodeId=dae2100e07011, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 11 21:21:03 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Nov 04 16:01:33 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25666, encryptionId=3ec02566625, topicName=伊沙佐米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b311689214, createdName=vividelife, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528760, encodeId=69e21528e6077, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973170, encodeId=d94b9e3170df, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sat Jun 12 22:41:00 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972931, encodeId=63139e2931d4, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Fri Jun 11 19:53:53 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
2021-11-04 lidong40

#JCO#

44 0
[GetPortalCommentsPageByObjectIdResponse(id=1007070, encodeId=dae2100e07011, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 11 21:21:03 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Nov 04 16:01:33 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25666, encryptionId=3ec02566625, topicName=伊沙佐米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b311689214, createdName=vividelife, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528760, encodeId=69e21528e6077, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973170, encodeId=d94b9e3170df, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sat Jun 12 22:41:00 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972931, encodeId=63139e2931d4, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Fri Jun 11 19:53:53 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
2021-06-13 juliusluan78

#生存期#

61 0
[GetPortalCommentsPageByObjectIdResponse(id=1007070, encodeId=dae2100e07011, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 11 21:21:03 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Nov 04 16:01:33 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25666, encryptionId=3ec02566625, topicName=伊沙佐米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b311689214, createdName=vividelife, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528760, encodeId=69e21528e6077, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973170, encodeId=d94b9e3170df, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sat Jun 12 22:41:00 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972931, encodeId=63139e2931d4, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Fri Jun 11 19:53:53 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
2021-06-13 12498cb5m16暂无昵称

#总生存期#

51 0
[GetPortalCommentsPageByObjectIdResponse(id=1007070, encodeId=dae2100e07011, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 11 21:21:03 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Nov 04 16:01:33 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25666, encryptionId=3ec02566625, topicName=伊沙佐米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b311689214, createdName=vividelife, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528760, encodeId=69e21528e6077, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973170, encodeId=d94b9e3170df, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sat Jun 12 22:41:00 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972931, encodeId=63139e2931d4, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Fri Jun 11 19:53:53 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
2021-06-13 vividelife

#伊沙佐米#

50 0
[GetPortalCommentsPageByObjectIdResponse(id=1007070, encodeId=dae2100e07011, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 11 21:21:03 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Nov 04 16:01:33 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25666, encryptionId=3ec02566625, topicName=伊沙佐米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b311689214, createdName=vividelife, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528760, encodeId=69e21528e6077, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973170, encodeId=d94b9e3170df, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sat Jun 12 22:41:00 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972931, encodeId=63139e2931d4, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Fri Jun 11 19:53:53 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
2021-06-13 freve

#难治性#

36 0
[GetPortalCommentsPageByObjectIdResponse(id=1007070, encodeId=dae2100e07011, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 11 21:21:03 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Nov 04 16:01:33 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25666, encryptionId=3ec02566625, topicName=伊沙佐米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b311689214, createdName=vividelife, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528760, encodeId=69e21528e6077, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973170, encodeId=d94b9e3170df, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sat Jun 12 22:41:00 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972931, encodeId=63139e2931d4, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Fri Jun 11 19:53:53 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
2021-06-12 1453df99m58暂无昵称

在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。

72 0
[GetPortalCommentsPageByObjectIdResponse(id=1007070, encodeId=dae2100e07011, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Wed Aug 11 21:21:03 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891671, encodeId=4e0218916e16a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Thu Nov 04 16:01:33 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516037, encodeId=3bd1151603e9a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52764, encryptionId=bd0152e64f1, topicName=总生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdf610907545, createdName=12498cb5m16暂无昵称, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526055, encodeId=d0621526055ad, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25666, encryptionId=3ec02566625, topicName=伊沙佐米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2b311689214, createdName=vividelife, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528760, encodeId=69e21528e6077, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Sun Jun 13 09:01:33 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973170, encodeId=d94b9e3170df, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sat Jun 12 22:41:00 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972931, encodeId=63139e2931d4, content=在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Fri Jun 11 19:53:53 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
2021-06-11 随梦飞扬

在预定的亚组中观察到较低的风险比，提示ixazomib-Rd方案与安慰剂-Rd相比具有更大的OS效益

75 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析

相关威廉亚洲官网

科室

工具

服务